Dr Angela Brodie Comments on Breast Cancer Prevention Trial
A New England Journal of Medicine study released on June 4, 2011, reported a significant advance in breast cancer prevention. The study found that exemestane, an aromatase inhibitor, already approved to treat breast cancer, can reduce the risk of postmenopausal women ever developing the disease by 65 percent.
Dr. Angela Brodie, an internationally recognized University of Maryland breast cancer researcher, pioneered the development of aromatase inhibitors. In this 2-minute video, she comments on the significance of the prevention study findings and the benefits the new drug offers for women who are at increased risk for breast cancer.
This page was last updated: September 5, 2014